Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 8Observational 2Expanded_access 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Afatinib 3ceritinib 2Gefitinib 2zipalertinib 1zenocutuzumab 1ulixertinib 1trilaciclib 1telisotuzumab vedotin 1tazemetostat 1taletrectinib 1sotorasib 1selpercatinib 1rovalpituzumab tesirine 1rociletinib 1pralsetinib 1pegilodecakin 1patritumab deruxtecan 1osimertinib 1mobocertinib 1lorlatinib 1lazertinib 1epigallocatechin gallate 1ensartinib 1dabrafenib 1cemiplimab 1capmatinib 1brigatinib 1belagenpumatucel L 1balstilimab 1amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × dabrafenib × Thoracic × Clear all
NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡